The decreased expression of EMP1 in nasopharyngeal carcinoma, prostate cancer, breast cancer, and colorectal cancer cells can lead to a lower survival rate, a higher proportion of apoptosis, decreased migration and invasion abilities, and lower expression of vascular endothelial growth factor C protein (p < 0.05), indicating that EMP1 might play an important role as a negative regulator of these tumor cells [67–70]. The gene discussed is VEGFC; the disease is prostate cancer.